SLNO (Soleno Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

SLNO (Soleno Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$190M

Net Income (TTM)$21M

EPS (TTM)$0.23

Free Cash Flow (TTM)$47M

Gross Margin98.6%

Op. Margin5.4%

Net Margin11.0%

FCF Margin24.6%

P/S Ratio (TTM)11.2x

P/E Ratio (TTM)102.4x

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$8M
Q2 23	$0	$0	-$9M
Q3 23	$0	$0	-$10M
Q4 23	$0	$0	-$14M
Q1 24	$0	$0	-$23M
Q2 24	$0	-$494K	-$23M
Q3 24	$0	$0	-$80M
Q4 24	$0	$0	-$59M
Q1 25	$0	$0	-$46M
Q2 25	$33M	$32M	-$7M
Q3 25	$66M	$65M	$22M
Q4 25	$92M	$91M	$40M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	65.5x	—
Q3 25	21.7x	—
Q4 25	11.2x	102.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$7M	-$7M
Q2 23	-$6M	-$6M
Q3 23	-$6M	-$6M
Q4 23	-$6M	-$6M
Q1 24	-$13M	-$13M
Q2 24	-$18M	-$18M
Q3 24	-$15M	-$15M
Q4 24	-$24M	-$24M
Q1 25	-$33M	-$33M
Q2 25	-$13M	-$13M
Q3 25	$44M	$44M
Q4 25	$49M	$49M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$11K
Q2 24	$8K
Q3 24	$191K
Q4 24	$8K
Q1 25	$5K
Q2 25	$9K
Q3 25	$1K
Q4 25	$58K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+46.7%
Q2 23	—	+27.2%
Q3 23	—	+66.5%
Q4 23	—	+148.0%
Q1 24	—	+177.2%
Q2 24	—	+169.4%
Q3 24	—	+672.6%
Q4 24	—	+325.0%
Q1 25	—	+94.9%
Q2 25	—	+68.7%
Q3 25	—	-45.3%
Q4 25	—	-13.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$631K	—
Q2 23	$1M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$6M	—
Q2 24	$7M	—
Q3 24	$57M	—
Q4 24	$30M	—
Q1 25	$15M	—
Q2 25	$10M	29.7%
Q3 25	$0	0.0%
Q4 25	$11M	12.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$5M	$3M	—
Q2 23	$5M	$3M	—
Q3 23	$6M	$3M	—
Q4 23	$9M	$4M	—
Q1 24	$15M	$8M	—
Q2 24	$12M	$11M	—
Q3 24	$30M	$49M	—
Q4 24	$21M	$37M	—
Q1 25	$14M	$29M	—
Q2 25	$9M	$28M	—
Q3 25	$8M	—	$34M
Q4 25	$10M	—	$41M

Revenue Segments

Quarter	Product
Q2 25	$33M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$8M	$0	$8M
Q2 23	$19M	$0	$19M
Q3 23	$52M	$0	$52M
Q4 23	$170M	$0	$170M
Q1 24	$43M	$107M	$150M
Q2 24	$57M	$209M	$266M
Q3 24	$48M	$208M	$257M
Q4 24	$88M	$204M	$291M
Q1 25	$81M	$209M	$290M
Q2 25	$76M	$210M	$287M
Q3 25	$247M	$252M	$499M
Q4 25	$70M	$235M	$305M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	9M	+0.1%
Q2 23	10M	+10.3%
Q3 23	11M	+9.7%
Q4 23	26M	+130.4%
Q1 24	36M	+37.4%
Q2 24	39M	+6.7%
Q3 24	42M	+8.4%
Q4 24	44M	+4.9%
Q1 25	46M	+5.1%
Q2 25	50M	+9.3%
Q3 25	55M	+8.8%
Q4 25	54M	-1.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	12
FY 15	$13K	29
FY 16	$56K	26
FY 17	-$129M	12
FY 18	$0	9
FY 19	$0	12
FY 20	$0	17
FY 21	$0	20
FY 22	$0	25
FY 23	$0	33
FY 24	$0	92
FY 25	$476	400K